Published in J Immunol Methods on October 29, 2011
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 4.05
Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood (2012) 1.80
Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles (2014) 1.79
Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost (2013) 1.53
Impact of biofluid viscosity on size and sedimentation efficiency of the isolated microvesicles. Front Physiol (2012) 1.36
Isolation of biologically-active exosomes from human plasma. J Immunol Methods (2014) 1.35
Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR. Methods Mol Biol (2013) 1.03
Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. Diabetes Metab Syndr Obes (2012) 1.01
Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology (2013) 1.01
Methods for extracellular vesicles isolation in a hospital setting. Front Immunol (2015) 1.00
Exosomal miRNAs as potential biomarkers of cardiovascular risk in children. J Transl Med (2014) 0.96
Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. Braz J Med Biol Res (2013) 0.96
Extracellular vesicle isolation and characterization: toward clinical application. J Clin Invest (2016) 0.95
miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neurooncol (2015) 0.90
Age- and sex-specific differences in blood-borne microvesicles from apparently healthy humans. Biol Sex Differ (2015) 0.88
Microvesicles as potential ovarian cancer biomarkers. Biomed Res Int (2013) 0.86
Extracellular Vesicles in Renal Diseases: More than Novel Biomarkers? J Am Soc Nephrol (2015) 0.86
Isolation of extracellular vesicles: Determining the correct approach (Review). Int J Mol Med (2015) 0.85
Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget (2014) 0.84
Extracellular vesicles in diagnosis and therapy of kidney diseases. Am J Physiol Renal Physiol (2016) 0.83
Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. Biol Sex Differ (2015) 0.82
The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn (2015) 0.81
Techniques to improve detection and analysis of extracellular vesicles using flow cytometry. Cytometry A (2015) 0.80
Longitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesicles. Platelets (2015) 0.80
Effect of storage on physical and functional properties of extracellular vesicles derived from neutrophilic granulocytes. J Extracell Vesicles (2014) 0.79
Specific renal parenchymal-derived urinary extracellular vesicles identify age-associated structural changes in living donor kidneys. J Extracell Vesicles (2016) 0.79
Avoiding false positive antigen detection by flow cytometry on blood cell derived microparticles: the importance of an appropriate negative control. PLoS One (2015) 0.78
Exosome poly-ubiquitin inhibits platelet activation, downregulates CD36 and inhibits pro-atherothombotic cellular functions. J Thromb Haemost (2014) 0.78
Pregnancy history and blood-borne microvesicles in middle aged women with and without coronary artery calcification. Atherosclerosis (2016) 0.77
Surface Phosphatidylserine Is Responsible for the Internalization on Microvesicles Derived from Hypoxia-Induced Human Bone Marrow Mesenchymal Stem Cells into Human Endothelial Cells. PLoS One (2016) 0.77
The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. Leukemia (2014) 0.77
Specific cell-derived microvesicles: Linking endothelial function to carotid artery intima-media thickness in low cardiovascular risk menopausal women. Atherosclerosis (2015) 0.77
On-chip immunoelectrophoresis of extracellular vesicles released from human breast cancer cells. PLoS One (2015) 0.76
Impact of collection, isolation and storage methodology of circulating microvesicles on flow cytometric analysis. Exp Ther Med (2015) 0.76
Women's Health Initiative Hormone Therapy Trials: New insights on Cardiovascular Disease from Additional Years of Follow up. Curr Cardiovasc Risk Rep (2013) 0.76
Erythrocyte nanovesicles: Biogenesis, biological roles and therapeutic approach: Erythrocyte nanovesicles. Saudi Pharm J (2015) 0.76
Trehalose prevents aggregation of exosomes and cryodamage. Sci Rep (2016) 0.75
Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites. Nat Commun (2017) 0.75
Liquid crystal droplet-based amplification of microvesicles that are shed by mammalian cells. Analyst (2014) 0.75
Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci U S A (2017) 0.75
Circulating Microvesicles Are Elevated Acutely following Major Burns Injury and Associated with Clinical Severity. PLoS One (2016) 0.75
Platelets and erythrocyte-bound platelets bind infectious HIV-1 in plasma of chronically infected patients. PLoS One (2013) 0.75
Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism. BMC Cancer (2017) 0.75
Characterization of intravascular cellular activation in relationship to subclinical atherosclerosis in postmenopausal women. PLoS One (2017) 0.75
Crosstalk of Nanosystems Induced Extracellular Vesicles as Promising Tools in Biomedical Applications. J Membr Biol (2017) 0.75
Shedding microvesicles: artefacts no more. Trends Cell Biol (2009) 8.84
Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood (1997) 4.01
Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine (2011) 3.79
A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer. J Thromb Haemost (2011) 3.16
Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation (2000) 3.08
Circulating microparticles: pathophysiology and clinical implications. Blood Rev (2006) 3.07
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
Microparticles in cardiovascular diseases. Cardiovasc Res (2003) 2.62
Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2.61
Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost (2001) 2.38
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost (2009) 2.33
Flow cytometric measurement of microparticles: pitfalls and protocol modifications. Platelets (2008) 2.28
Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol (2006) 2.23
Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J Thromb Haemost (2008) 2.11
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res (2009) 2.04
Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost (2010) 1.80
Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res (2011) 1.76
Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost (2010) 1.56
Plasma microparticles and vascular disorders. Br J Haematol (2007) 1.52
Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol (2008) 1.44
Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag (2010) 1.26
Characterizing blood microparticles: technical aspects and challenges. Vasc Health Risk Manag (2008) 1.17
New horizons in the analysis of circulating cell-derived microparticles. Keio J Med (2004) 1.16
Cancer-associated thrombosis. Crit Rev Oncol Hematol (2007) 1.15
Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost (2007) 1.10
Use of silica microspheres having refractive index similar to bacteria for conversion of flow cytometric forward light scatter into biovolume. Water Res (2008) 1.10
Flow cytometric detection of endothelial microparticles (EMP): effects of centrifugation and storage alter with the phenotype studied. Thromb Res (2010) 1.09
Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost (2008) 1.08
Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res (2008) 1.04
Circulating microparticles and endogenous estrogen in newly menopausal women. Climacteric (2009) 0.98
Centrifugation is a crucial step impacting microparticle measurement. Platelets (2009) 0.98
Procoagulant activity, but not number, of microparticles increases with age and in individuals after a single venous thromboembolism. Thromb Res (2010) 0.93
Optimized flow cytometric assay for the measurement of platelet microparticles in plasma: pre-analytic and analytic considerations. Blood Coagul Fibrinolysis (2002) 0.85
Animal models for studies on cold-induced platelet activation in human beings. J Lab Clin Med (2000) 0.80
Development of a time-resolved immunofluorometric assay for quantifying platelet-derived microparticles in human plasma. Thromb Res (2005) 0.80
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med (2010) 4.77
Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol (2005) 4.39
Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med (2003) 3.85
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
The Gene, Environment Association Studies consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions. Genet Epidemiol (2010) 3.48
Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med (2014) 2.48
Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke (2006) 2.17
Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol (2007) 2.06
Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc (2008) 1.97
Premature menopause or early menopause and risk of ischemic stroke. Menopause (2012) 1.84
Considerations of sex and gender differences in preclinical and clinical trials. Handb Exp Pharmacol (2012) 1.77
Prevention of venous thromboembolism. Chest (2005) 1.76
Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc (2011) 1.62
Women, hormones, and clinical trials: a beginning, not an end. J Appl Physiol (1985) (2005) 1.60
Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case-control study. J Thromb Haemost (2005) 1.56
Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med (2010) 1.55
Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab (2013) 1.51
Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol (2011) 1.47
Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol (2008) 1.44
The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery. Arch Intern Med (2002) 1.44
Factors contributing to individual propensity for arterial thrombosis. Arterioscler Thromb Vasc Biol (2002) 1.42
Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum (2012) 1.34
The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid Redox Signal (2009) 1.32
Cell biology of pathologic renal calcification: contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. J Investig Med (2006) 1.29
Phenotype harmonization and cross-study collaboration in GWAS consortia: the GENEVA experience. Genet Epidemiol (2011) 1.29
Hormonal modulation of endothelial NO production. Pflugers Arch (2010) 1.26
Identifying in-hospital venous thromboembolism (VTE): a comparison of claims-based approaches with the Rochester Epidemiology Project VTE cohort. Med Care (2008) 1.24
Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med (2002) 1.23
Physical evidence that yeast frataxin is an iron storage protein. Biochemistry (2002) 1.23
Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause (2006) 1.18
Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis (2009) 1.18
In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol (1985) (2006) 1.13
Maternal recall of hypertensive disorders in pregnancy: a systematic review. J Womens Health (Larchmt) (2012) 1.11
Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res (2011) 1.11
Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol (2009) 1.09
In pursuit of scientific excellence: sex matters. Am J Physiol Cell Physiol (2012) 1.08
Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: proof of principle. Int J Nanomedicine (2008) 1.08
Sex differences and sex steroids in lung health and disease. Endocr Rev (2012) 1.07
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc (2009) 1.07
Proteomic evaluation of biological nanoparticles isolated from human kidney stones and calcified arteries. Acta Biomater (2010) 1.02
Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med (2011) 1.02
Search for microbial signatures within human and microbial calcifications using soft x-ray spectromicroscopy. J Investig Med (2006) 1.01
Sex/gender medicine. The biological basis for personalized care in cardiovascular medicine. Circ J (2009) 1.01
Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology (2013) 1.01
Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. J Clin Endocrinol Metab (2006) 1.00
Quantification of hypercoagulable state after blunt trauma: microparticle and thrombin generation are increased relative to injury severity, while standard markers are not. Surgery (2012) 0.99
Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease. J Clin Endocrinol Metab (2004) 0.99
In pursuit of scientific excellence: sex matters. Am J Physiol Heart Circ Physiol (2012) 0.98
Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol (2009) 0.97
Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol (2010) 0.97
Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb Res (2010) 0.96
Risk factors and underlying mechanisms for venous stasis syndrome: a population-based case-control study. Vasc Med (2009) 0.96
Differential effects of 17beta-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am J Physiol Heart Circ Physiol (2005) 0.95
The rat aortic ring assay for in vitro study of angiogenesis. Methods Mol Med (2003) 0.95
Outcomes after withholding anticoagulation from patients with suspected acute pulmonary embolism and negative computed tomographic findings: a cohort study. Mayo Clin Proc (2002) 0.94
Systemic injection of planktonic forms of mammalian-derived nanoparticles alters arterial response to injury in rabbits. Am J Physiol Heart Circ Physiol (2009) 0.94
Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiol Genomics (2012) 0.93
Loss of estrogen receptor beta decreases mitochondrial energetic potential and increases thrombogenicity of platelets in aged female mice. Age (Dordr) (2009) 0.93
Acrocyanosis: the Flying Dutchman. Vasc Med (2011) 0.93
Estrogen, inflammation, and platelet phenotype. Gend Med (2008) 0.92
Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging. Thromb Res (2010) 0.92
Risk factors for venous thromboembolism in nursing home residents. Mayo Clin Proc (2008) 0.92
Sex-specific changes in platelet aggregation and secretion with sexual maturity in pigs. J Appl Physiol (1985) (2004) 0.91
Key role of alkaline phosphatase in the development of human-derived nanoparticles in vitro. Acta Biomater (2010) 0.90
Characterization of biofilm formed by human-derived nanoparticles. Nanomedicine (Lond) (2009) 0.90
Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility. Transfusion (2003) 0.90
Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog). Brain Res (2013) 0.89
Fellatio-associated petechiae of the palate: report of purpuric palatal lesions developing after oral sex. Dermatol Online J (2013) 0.89
Binding stoichiometry of an RNA aptamer and its transcription factor target. Anal Biochem (2002) 0.89
Pilot study of sex differences in chemokine/cytokine markers of atherosclerosis in humans. Gend Med (2008) 0.89
Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets. Am J Physiol Heart Circ Physiol (2002) 0.88
Identification of a novel percent mammographic density locus at 12q24. Hum Mol Genet (2012) 0.88
Should there be sex-specific criteria for the diagnosis and treatment of heart failure? J Cardiovasc Transl Res (2013) 0.87
Platelet characteristics change with aging: role of estrogen receptor beta. J Gerontol A Biol Sci Med Sci (2005) 0.87
Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res (2009) 0.87
Go Red for Women cardiovascular health-screening evaluation: the dichotomy between awareness and perception of cardiovascular risk in the community. J Womens Health (Larchmt) (2013) 0.87